Zivo Bioscience Secures Funding Through Share Sales
Zivo Bioscience, Inc., a biotechnology firm, has initiated the sale of 169,022 shares of its common stock to accredited investors, indicating its ongoing efforts to secure financing for growth. These transactions occurred over recent months, with shares being sold at rates between $8.34 and $16.31, averaging $10.44 per share. This strategic maneuver is part of the company's broader plan to strengthen its financial position in the biotech market.
Details of the Share Transactions
As highlighted in Zivo's recent SEC filing, the company reported selling 52,802 shares to related parties, where prices ranged from $8.34 to $15.96, with an average price of $9.68 per share. Significantly, these transactions were executed without public solicitation. The company clarified that no underwriting discounts were offered, a move that often attracts certain types of investors.
Regulatory Compliance
The share sales were compliant with Section 4(a)(2) of the Securities Act of 1933 and Regulation D (Rule 506), enabling the company to undertake these sales without the need for public offering regulations, thus allowing for flexible financing options. Zivo Bioscience's total number of outstanding common stock shares has reached 3,535,134 after these recent activities.
Company Background and Stock Information
Previously known as Health Enhancement Products Inc. and Western Glory Hole Inc., Zivo Bioscience operates within the biological products sector, avoiding diagnostics. The company's stock is traded on the OTCQB with the ticker symbol ZIVO, while its warrants are listed on the OTC Pink Sheets under the symbol ZIVOW.
Understanding Zivo’s Growth and Market Position
The latest share offering sheds light on Zivo Bioscience's capital-raising initiatives, essential for advancing its operations and ensuring sustainable growth in a competitive industry. Notably, analyzing the financial implications reveals that Zivo's market capitalization is approximately $69.81 million, categorizing it as a small-cap entity in the biotech landscape.
Market Performance and Growth Metrics
Data indicates that Zivo has experienced extraordinary revenue growth of 1,364.69% over the past twelve months as of Q2 2024. This remarkable performance positions the company as a distinctive player in the industry. Furthermore, the stock has shown a solid return of 40.79% in total price return over the last month, enhancing its appeal to potential investors. The strong performance could well be a significant factor in attracting accredited investors in the recent share sale.
Financial Challenges Facing Zivo
Despite the exceptionally impressive growth metrics, Zivo Bioscience does face challenges in terms of profitability and debt. The company recorded an operating income margin of -21,871.9%, reflecting the financial pressures typical for emerging biotech firms. Given these factors, potential investors should approach with caution, keeping the company's moderate debt levels in mind as they consider the investment opportunity.
Conclusion
Zivo Bioscience's recent share sales exemplify its strategic efforts to foster financial growth and indicate a proactive approach to funding its operations in the biotechnology sector. As it navigates the complexities of the market, the company's growth trajectory and investor interest will play pivotal roles in shaping its future.
Frequently Asked Questions
What are the recent share sales by Zivo Bioscience?
Zivo Bioscience has sold 169,022 shares of common stock to accredited investors at prices between $8.34 and $16.31 to secure funding for growth.
How much average revenue growth has Zivo experienced recently?
The company reported a staggering 1,364.69% revenue growth over the past twelve months, indicating significant performance improvement.
What is Zivo's market capitalization?
Zivo's current market capitalization stands at approximately $69.81 million, placing it in the small-cap category in the biotech sector.
What regulatory compliance did Zivo follow for its share sales?
The sales were compliant with Section 4(a)(2) of the Securities Act of 1933 and Regulation D (Rule 506), enabling the transactions without public offering requirements.
What financial challenges does Zivo face?
Zivo operates with a moderate level of debt and recently reported an operating income margin of -21,871.9%, which underscores its challenges in achieving profitability.
